Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **fungal cell membrane** is a lipid bilayer structure unique among eukaryotes for its high content of **ergosterol**, which replaces cholesterol found in animal membranes. This feature makes it a key target for antifungal therapy. The **membrane contains various integral proteins** involved in nutrient uptake, signal transduction, enzymatic activity related to biosynthesis pathways such as those producing glucans and chitin for the adjacent cell wall, and maintenance of ion gradients essential for cellular function[5][7]. Antifungal drugs exploit differences between fungal membranes and those of humans—most notably targeting ergosterol or its biosynthetic pathway. For example: > “Fungi have plasma membranes similar to other eukaryotes except that the structure is stabilized by ergosterol—a steroid molecule that replaces cholesterol found in animal cell membranes... The rigid layers of fungal cell walls contain complex polysaccharides called chitin and glucans.”[5] > “Present review focuses on [the] cell membrane as an antifungal target with emphasis on... biogenesis, structure and function... Most antifungals act either by binding directly to ergosterol or inhibiting its synthesis.”[7] While "fungal cell membrane/proteins" refers broadly rather than specifically—encompassing many different molecular entities—it remains a valid therapeutic target class because most clinically used antifungals act at this level. However, **there is something incorrect about using "Fungal cell membrane/proteins" as a single canonical target name:** it lacks specificity. It does not refer to one defined molecular entity but rather an entire class or set of molecules within a structural compartment. For structured data purposes—such as drug-target databases—the term should be replaced with specific protein names like “Ergosterol,” “Lanosterol 14α-demethylase,” or individual transporter/receptor/enzyme names when possible. In summary, the **fungal cell membrane** represents an important therapeutic target due primarily to its unique sterols and associated proteins critical for survival; however, “Fungal cell membrane/proteins” is too broad/vague for use as a canonical molecular entry.[5][7]
- Disruption of ergosterol in the fungal cell membrane leading to increased permeability and cell death (Amphotericin B)[7] - Inhibition of ergosterol biosynthesis by blocking lanosterol 14α-demethylase enzyme activity (Azoles)[7] - Inhibition of β-(1,3)-D-glucan synthesis in the fungal cell wall via glucan synthase inhibition (Echinocandins; note this targets the wall but is often grouped with membrane-active agents due to clinical context)[1][7]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fungal cell membrane protein.